Rayan Salih, MD, a third-year internal medicine resident with the Northeast Georgia Health System, who hopes to specialize in cardiology, presented the poster, “Double Trouble: Pregnancy Challenges in ...

Dapagliflozin-spironolactone reduces NT-proBNP levels and blood pressure more than dapagliflozin alone but at the cost of a ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

New FDA Indication: Kerendia (finerenone) is now approved to reduce cardiovascular death, heart failure (HF) hospitalization, and urgent HF visits in adults with HF and left ventricular ejection ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat distribution, with greater weight loss linked to better outcomes, a study ...

The incretin-based therapies reduced mortality and hospitalization risk in individuals with heart failure with preserved ...

For the HF patient with a gain in LVEF, there’s little guidance on how best to care for them or manage their GDMT.

A tiny implantable heart device is changing lives for patients with HFpEF heart failure. Scripps La Jolla is among 65 ...

Glucagon-like peptide-1 (GLP-1) inhibitors have proven effective in preventing cardiovascular events, leading to experts ...

Discover how tirzepatide benefits heart failure in obesity, and see why those with higher BMI may gain even more benefits.

Included in the open-label crossover SOGALDI-PEF study were adults with symptomatic heart failure (New York Heart Association ...